Compare JAGX & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | ORIS |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.6M |
| IPO Year | N/A | 2024 |
| Metric | JAGX | ORIS |
|---|---|---|
| Price | $1.18 | $0.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 380.3K | ★ 2.1M |
| Earning Date | 11-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $11,785,000.00 | ★ $12,317,000.00 |
| Revenue This Year | $22.41 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | ★ N/A | $510.25 |
| Revenue Growth | ★ 12.45 | N/A |
| 52 Week Low | $1.00 | $0.08 |
| 52 Week High | $33.25 | $2.85 |
| Indicator | JAGX | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 39.78 |
| Support Level | $1.05 | $0.11 |
| Resistance Level | $1.36 | $0.13 |
| Average True Range (ATR) | 0.16 | 0.01 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 38.00 | 16.02 |
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).